Ropivacaine (hydrochloride monohydrate)

Ropivacaine hydrochloride monohydrate is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese[1][2]. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane[3]. Ropivacaine is widely used for regional anesthesia and neuropathic pain management in vivo[1].

Product Specifications

CAS Number

[132112-35-7]

UNSPSC

12352005

Hazard Statement

H318

Target

Potassium Channel; Sodium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Ropivacaine-hydrochloride-monohydrate.html

Concentration

10mM

Purity

99.82

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic)

Smiles

O=C([C@H]1N(CCC)CCCC1)NC2=C(C)C=CC=C2C.O.Cl

Molecular Formula

C17H29ClN2O2

Molecular Weight

328.88

Precautions

H318

References & Citations

[1]Li TF, et al. Epidural sustained release ropivacaine prolongs anti-allodynia and anti-hyperalgesia in developing and established neuropathic pain. PLoS One. 2015 Jan 24;10 (1) :e0117321.|[2]Milan Patel, et al. Ropivacaine Inhibits Pressure-Induced Lung Endothelial Hyperpermeability in Models of Acute Hypertension. Life Sci. 2019 Apr 1;222:22-28.|[3]Dene Simpson, et al. Ropivacaine: a review of its use in regional anaesthesia and acute pain management. Drugs. 2005;65 (18) :2675-717.|[4]Hye Won Shin, et al. The inhibitory effects of bupivacaine, levobupivacaine, and ropivacaine on K2P (two-pore domain potassium) channel TREK-1. J Anesth. 2014 Feb;28 (1) :81-6.